New ASH Summit Encourages Practical, Elevated Dialogue on Emerging Immunotherapies
The ASH Summit on Emerging Immunotherapies for Hematologic Diseases program co-chairs Drs. Catherine Bollard, Rodrigo Calado, Sergio Giralt, and Jeffrey Miller share their
Novel Insights From Comprehensive Genomic Profiling of T Cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that helps expand understanding of T-cell acute lymphoblastic leukemia biology.
A concise review of a topic that illustrates the relationship of basic research to clinical hematology
Dr. Jordan examines the emergence of targeted therapy for hemophagocytic lymphohistiocytosis, a striking inflammatory disorder familiar to hematologists.
Dr. Paneez Khoury provides an overview of the diagnosis and treatment of lymphocytic variant hypereosinophilic syndromes.
Dr. Schiffman and Dr. Maese discuss pediatric cancer susceptibility disorders and their relevance to hematology as highlighted in a 2016 American Association for Cancer Research workshop.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Drs. Sojitra, Arber, and George cover the 2017 joint guidelines from ASH and the College of American Pathologists on testing for the initial workup of acute leukemia.
Dr. Hoggatt discusses stem cell transplantation and looks at new, targeted conditioning approaches that have recently emerged, where the potential patient pool could be remarkably expanded with the advent of new gene therapy and editing strategies.
Dr. George and Dr. Czuchlewski cover the World Health Organization's 2016 updates to the classification of myeloid neoplasms.
Dr. Garcia highlights clinical recommendations from the ACCP's evidence-based guidelines for the treatment of venous thromboembolism (VTE) that are most relevant to hematologists.
Dr. Yang and Dr. Press evaluate the clinical utility of next-generation DNA sequencing (NGS) methods to profile the multiple actionable driver genes in patients with known and/or suspected myeloid malignancies.
Drs. Yao, Cardó-Vila, Ahmadian, Ebaid, Arap, and Pasqualini discuss the existence of tumor-specific molecular zip codes that can be used to design drugs to treat leukemia, lymphoma, and solid tumors.
January-February 2018Volume 15, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology